DNA-data-strand-web
FAQ's
Answer : According to Precedence Research, the pain management therapeutics market size was reached at USD 72.41 billion in 2021 and is anticipated to hit over USD 105.77 billion by 2030.
Answer : The pain management therapeutics domain includes the contraction and treatment of pain with the use of various groupings of drugs and workouts which deliver relief to the sufferer by directing at the receptors. The demand for pain management has seen an exponential rise mainly due to changing lifestyle patterns and growing number of chronic ailments.
Answer : The global pain management therapeutics market is expected to drive growth at a CAGR of 4.3% during the forecast period 2022 to 2030.
Answer : Factors such as increasing geriatric population, rising number of accidents worldwide, growing prevalence of chronic disorders, rise in per-capita healthcare expenditure, increasing number of surgeries, constant approvals for new easy-to-use and effective medications, increasing cases of cancer in developing regions, and growing research and development expenditure are propelling the pain management therapeutics market expansion across the globe.
Answer : In 2020, North America dominated the global market with a market share of more than 43%.
Answer : The neuropathic pain segment accounted for the largest revenue within the indication segment with more than 32% share in 2020. Factors such as large patient pool and technological innovations drive the growth of interventional study. Chronic back pain and cancer pain indications are projected to grow at significant rate in the forecast time-frame.
Answer : The major companies operating in the worldwide pain management therapeutics market are Teva Pharmaceutical, Pfizer, Abbott, Mallinckrodt Pharmaceuticals, Endo International, GlaxoSmithKline, AstraZeneca, Depomed, Merck, and Novartis among others.
Get a Sample of this Report
DNA-data-strand-web
